DNA Replication Stalling Attenuates Tyrosine Kinase Signaling to Suppress S Phase Progression  by Shields, Ben J. et al.
Cancer Cell
ArticleDNA Replication Stalling
Attenuates Tyrosine Kinase Signaling
to Suppress S Phase Progression
Ben J. Shields,1 Christine Hauser,1 Patricia E. Bukczynska,1,2 Naomi W. Court,1,2 and Tony Tiganis1,*
1Department of Biochemistry and Molecular Biology, Monash University, Victoria 3800, Australia
2Present address: Cytopia Research, 576 Swan Street, Richmond, Victoria 3121, Australia
*Correspondence: tony.tiganis@med.monash.edu.au
DOI 10.1016/j.ccr.2008.06.003SUMMARY
Here we report that T cell protein tyrosine phosphatase (TCPTP)-dependent and -independent pathways
attenuate the JAK and Src protein tyrosine kinases (PTKs) and STAT3 phosphorylation to suppress cyclin
D1 expression and S phase progression in response to DNA replication stress. Cells that lack TCPTP fail
to suppress JAK1, Src, and STAT3, allowing for sustained cyclin D1 levels and progression through S phase
despite continued replication stress. Cells that bypass the checkpoint undergo aberrantmitoses with lagging
chromosomes that stain for the DNA damage marker gH2AX. Therefore, inactivating JAK, Src, and STAT3
signaling pathways in response to DNA replication stress may be essential for the suppression of S phase
progression and the maintenance of genomic stability.INTRODUCTION
During cellular division, specific and intricate surveillance mech-
anisms, known as checkpoints, facilitate orderly cell-cycle pro-
gression and ensure the faithful transmission of replicated DNA
to daughter cells. Failure of such checkpoints can lead to geno-
mic instability that is associated with many human cancers. The
mammalian phosphatidylinositol 3-kinase (PI3K)-related serine/
threonine protein kinases ATM (ataxia-telangiectasia mutated)
and ATR (ataxia-telangiectasia Rad3-related) are integral regula-
tors of cell-cycle checkpoints. In S phase, they are activated in
response to varied forms of cellular stress: ATM is activated pri-
marily by DNA double-strand breaks (DSBs) caused by ionizing
radiation or radiomimetic drugs, whereas ATR is activated by
replication stalls as well as a broad range of other forms of
DNA damage. ATM and ATR phosphorylate numerous sub-
strates, including histone H2AX and the protein kinases Chk1
and 2, which in turn phosphorylate other proteins, including the
transcription factor p53 and the Cdc25 phosphatases, to medi-
ate checkpoint responses (Kastan and Bartek, 2004).166 Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc.During S phase, the genome is under constant scrutiny to en-
sure that DNA is copied accurately and completely before cells
enter mitosis. Both DNA damage and DNA replication check-
point mechanisms serve to maintain the fidelity of DNA. The
DNA damage checkpoints suppress S phase progression and
coordinate the repair of DNA in response to genotoxic insults
that cause damage away from active replicons. The DNA replica-
tion checkpoint is ATR dependent and functions specifically in
response to stalls in DNA synthesis to inhibit origin firing, stabi-
lize replication forks, and orchestrate DNA repair (Bartek et al.,
2004; Osborn et al., 2002). The yeast ATM/ATR homologs
Mec1 (S. cerevisiae) and Rad3 (S. pombe) are essential for S
phase arrest in response to replication inhibitors; Mec1 and
Rad3mutant yeast exposed to replication inhibitors fail to arrest
in S phase and proceed to partition unreplicated chromosomes
(al-Khodairy and Carr, 1992; Enoch et al., 1992; Weinert et al.,
1994). In contrast, mouse embryonic fibroblasts (MEFs) deficient
in ATR, ATM and ATR, or ATR and p53 remain arrested in S
phase after the inhibition of DNA synthesis with the polymerase
a inhibitor aphidicolin (Brown and Baltimore, 2003). Thus,SIGNIFICANCE
The JAK and Src protein tyrosine kinases (PTKs) and their substrates STAT3 and cyclin D1 are overexpressed and/or acti-
vated in a wide variety of human tumors contributing to the proliferative drive. Here we report that the inactivation of PTK
pathways and the depletion of cyclin D1 can contribute to the delay in cell division when DNA replication is compromised.
When PTK pathways are not turned off and cyclin D1 is sustained, unscheduled cell division can ensue wherein cells par-
tition their DNA unevenly. Our results identify a mechanism by which oncogenic PTK signaling may bypass the replication
checkpoint and contribute to genetic instability in cancer.
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STAT3 and the Replication Checkpointadditional pathways contribute to the suppression of S phase
progression when DNA replication is compromised in mamma-
lian cells.
The T cell protein tyrosine phosphatase (TCPTP; Ptpn2) is an
intracellular nontransmembrane tyrosine-specific phosphatase
(Tiganis and Bennett, 2007). Although most abundant in the
hematopoietic compartment, TCPTP is present in all tissues
and at all stages of mammalian development. TCPTP can specif-
ically regulate growth factor- and cytokine-induced protein tyro-
sine kinase (PTK)-mediated signaling pathways by dephosphor-
ylating distinct substrates that include the Janus-activated PTKs
(JAKs) 1 and 3 and the JAK substrates signal transducer and ac-
tivator of transcription (STAT) 1, 3, and 6 (Lu et al., 2007; Tiganis
and Bennett, 2007). More recently, our laboratory also identified
Src-family PTKs (SFKs) as cellular substrates for TCPTP and
reported increased SFK activation in TCPTP-deficient cells
(van Vliet et al., 2005). The JAKs, SFKs, and their common sub-
strate STAT3 are frequently hyperactivated in a wide variety of
human malignancies promoting cell-cycle progression and pro-
liferation (Bromberg et al., 1999; Valentino and Pierre, 2006;
Yeatman, 2004). Here we report that the inactivation of the
SFK and JAK PTKs and STAT3 by TCPTP, for the inhibition of
cyclin D1 expression, contributes to the suppression of S phase
progression in response to DNA replication stress. Furthermore,
we identify a mechanism by which oncogenic PTK pathways
may bypass the replication checkpoint and contribute to genetic
instability and tumorigenesis.
RESULTS
TCPTP Attenuates PTK Signaling in Response to DNA
Replication Stress
To determine TCPTP’s role in PTK signaling in response to rep-
lication stress, we used spontaneously immortalized Ptpn2/
MEFs versus those reconstituted stably with physiological
amounts of TCPTP (Galic et al., 2003). Cells were synchronized
in G0 by serum deprivation and released into the cell cycle by
the readdition of serum. In late G1 (12 hr release), cells were
treated with replication inhibitors for 6–36 hr (S phase entry nor-
mally occurred at 15–18 hr release), and PTK signaling was as-
sessed by immunoblot analysis using antibodies against the
phosphorylated and activated forms of c-Src (Tyr418), JAK1
(Tyr1022/Tyr1023), and STAT3 (Tyr705). Two replication inhibi-
tors were used: aphidicolin, which inhibits polymerase a, and
thymidine, which indirectly inhibits ribonucleotide reductase.
Previous studies have established that thymidine-induced stalls
can result in the generation of poorly defined replication interme-
diates but not DSBs (Liu and Lim, 2005; Lundin et al., 2002;
Saleh-Gohari et al., 2005; Xie et al., 2004), whereas aphidico-
lin-induced stalls collapse to form DSBs (Brown and Baltimore,
2003; Rothkamm et al., 2003; Saintigny et al., 2001). Consistent
with this, both agents activated the DNA replication checkpoint
as assessed by the phosphorylation and retarded electropho-
retic mobility of the ATR substrate Chk1, but only aphidicolin
activated ATM (Ser1981 phosphorylation) (Figure 1A). Also,
p53 activation (accumulation and Ser18 phosphorylation) and
histone H2AX phosphorylation (Ser139; gH2AX) were more
pronounced in the presence of aphidicolin (Figure 1A), in line
with aphidicolin’s propensity to induce DSBs.In TCPTP-reconstituted MEFs, thymidine- or aphidicolin-
instigated S phase arrest attenuated SFK, JAK1, and STAT3
phosphorylation (Figure 1B). This could not be ascribed to
changes in PTK signaling during normal G1/S and G2/M pro-
gression, as SFK, JAK1, and STAT3 phosphorylation remained
unaltered or increased modestly in cells otherwise proceeding
through G1 into S and thereon into G2 (data not shown). The
inactivation of PTK pathways in response to thymidine or aphidi-
colin occurred when ATR/Chk1 signaling had waned (after 12 hr)
and ATM activation, p53 induction, and gH2AX were greatest
(Figures 1A and 1B). PTK inactivation in response to DNA repli-
cation stress induced by thymidine was also noted in other cells
including HeLa cells and normal human 7625 (Figure 1C) and
MRC5 fibroblasts (data not shown). Since thymidine and aphidi-
colin act indirectly to slow S phase progression, we asked
whether PTK pathway suppression also occurred in response
to agents that modify DNA to directly impede the advancing
fork. Methyl methanesulfonate (MMS) is a DNA-alkylating agent
that has been used widely as a radiomimetic. However, recent
evidence indicates that MMS does not induce DSBs (Lundin
et al., 2005) but instead slows fork progression, increases stall-
ing, and inhibits origin firing in yeast and mammals (Merrick
et al., 2004; Tercero and Diffley, 2001). Accordingly, we exam-
ined the status of PTK signaling pathways in response to
MMS. MEFs were treated with MMS either at 15 hr release, at
the onset of S phase entry, or at 18 hr release, when the cells
were in S phase. In both cases, S phase progression was in-
hibited (data not shown) and JAK1, STAT3, and to a lesser extent
SFKswere inactivated, coincidingwith the induction of Chk1 sig-
naling (Figure 1D); MMS treatment also resulted in JAK1 and
STAT3 inactivation in HeLa cells during S phase (data not
shown). Addition of MMS to MEFs at earlier times, during G1,
did not inactivate PTK pathways until the equivalent of 15 hr re-
lease, when the cells would otherwise be entering S phase (see
Figure S1 available online). Thus, these results indicate that the
inactivation of PTKs may be a specific and active response to
DNA replication stress. Consistent with this interpretation, we
found that exposing S phase cells (G1/S synchronized and re-
leased into S) to ultraviolet light (UV), which generates pyrimidine
dimers that stall the advancing replication fork, also suppressed
PTK and STAT3 signaling (Figure 1E). In contrast, we found that
the topoisomerase II inhibitor etoposide, which is capable of
promoting replicon-independent damage (Tanaka et al., 2007),
accumulated cells in G1 and S but did not inhibit SFK or
STAT3 signaling even after 36 hr of treatment (Figure 1F). PTK
pathways also remained unaltered in response to other geno-
toxic agents, including adriamycin (data not shown), which gen-
erates DSBs in G1. Thus, the inactivation of PTK pathways may
be a specific response to replicative stress.
In TCPTP-deficient MEFs, SFKs, JAK1, and STAT3 remained
phosphorylated and activated even at 36 hr of thymidine treat-
ment (Figure 1B). Indeed, rather than being inactivated, STAT3
phosphorylation increased over time to >4-fold when compared
to untreated TCPTP-deficient cells proceeding through S phase
(Figure 1G). Importantly, the increase in STAT3 phosphorylation
was evident within hours of S phase onset (9 hr thymidine treat-
ment, equivalent to 21 hr release) in a time frame similar to ATR/
Chk1 signaling (Figure 1G). STAT3 phosphorylation did not oth-
erwise increase in TCPTP-deficient cells proceeding through SCancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc. 167
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STAT3 and the Replication CheckpointFigure 1. SFKs, JAK1, and STAT3 Are Attenuated in Response to DNA Replication Stress
(A and B) G0-synchronized and released Ptpn2/ (/) and 45 kDa TCPTP-reconstituted MEFs (+TCPTP; clones R5, R10, and R20) were treated with thymidine
(2 mM) or aphidicolin (2 mM), and lysates were processed for immunoblot analysis.
(C) HeLa and 7625 cells were synchronized by double thymidine block and released for 12 hr so that cells returned toG1 and then treatedwith thymidine (5mM) or
aphidicolin (2 mM) as indicated, and lysates were processed for immunoblot analysis.168 Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc.
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STAT3 and the Replication Checkpoint(see 18–24 hr release in Figure 1G), indicating that the hyperac-
tivation was a specific response to replication stress. Therefore,
these results suggest that TCPTP may be required to prevent
STAT3 hyperactivation when replication is stalled. In response
to aphidicolin, the SFK, JAK1, and STAT3 pathways were also
elevated when compared to TCPTP-reconstituted cells treated
with aphidicolin (Figure 1B), and STAT3 activation increased
over time until 24–36 hr of treatment (Figure S2), when ATM
signaling ensued (Figure 1A). However, in response to MMS or
UV, PTK pathway inactivation/suppression occurred irrespec-
tive of TCPTP status (Figure S3; data not shown). Therefore,
both TCPTP-dependent and -independent mechanisms may
exist for the attenuation of SFK, JAK1, and STAT3 signaling in
response to DNA replication stress.
DNA Replication Checkpoint Bypass
in TCPTP-Deficient Cells
Next we assessed the possible impact of TCPTP deficiency on
the DNA replication checkpoint. We saw no difference in the ac-
tivation of ATM/ATR checkpoint pathways as monitored by ATM
Ser1981 phosphorylation, Chk1 phosphorylation, p53 induction,
and gH2AX in TCPTP-deficient versus -reconstituted cells ar-
rested in S phase with thymidine, aphidicolin (Figure 1A), UV,
or MMS (data not shown). Consistent with this, TCPTP-deficient
and -reconstituted cells responded similarly to genotoxic agents
that instigated ATM/ATR-mediated checkpoint arrests in G1, S,
or G2 (data not shown). Thus, ATM/ATR checkpoint pathways
and responses are not generally altered in the absence of
TCPTP. Despite this, we found that TCPTP-deficient cells (or
vector control cells; see Figure S4) treated with thymidine by-
passed the replication checkpoint, traversing S phase and pro-
gressing into G2 as determined by an increase in DNA content
(Figures 2A and 2B) and an earlier peak in cyclin B1 expression
(Figure 2C). In contrast, TCPTP-reconstituted cells remained ar-
rested at G1/S in the presence of thymidine until approximately
36 hr treatment, when they began to progress through S phase
(Figures 2A and 2B). Furthermore, the replication checkpoint by-
pass was not a mere consequence of enhanced G1 or S phase
progression, since the G1 restriction point was not altered and
cells synchronized in S phase by brief thymidine or aphidicolin
treatment progressed similarly after release (data not shown).
The checkpoint bypass and progression of TCPTP null MEFs
through S phase in the presence of thymidine was apparent
within 12 hr of treatment, when the cells would otherwise be
completing S phase (Figures 2A and 2B). By 20–24 hr of treat-
ment, TCPTP-deficient cells that had bypassed the thymidine-
induced arrest appeared to have completed mitosis and reen-
tered G1 of the next cell cycle (Figure 2A). Consistent with this,we noted an increase in phosphorylated CDK1 (S/T)P epitopes
(MPM-2), an increase in histone H3 phosphorylation, and the
presence of mitotic figures (Figures 2D–2F). Roughly one-third
of all mitoses occurring in the presence of thymidine were aber-
rant and characterized predominantly by lagging chromosomes
(Figures 3A and 3B); mitotic aberrations were not evident in
untreated TCPTP-deficient cells or in TCPTP-reconstituted cells
treated with thymidine (data not shown). The incidence of lag-
ging chromosomes in cells that had been arrested in S phase
with thymidine for 24 hr and then allowed to proceed into mitosis
was reduced by approximately 50% (data not shown), consis-
tent with the aberrations being attributable to checkpoint
bypass. Notably, in many cases, the unaligned and lagging chro-
mosomes stained for gH2AX (Figure 3C), a marker for DSBs and
other forms of DNA damage (Liu and Lim, 2005; Lundin et al.,
2002; Saleh-Gohari et al., 2005; Ward and Chen, 2001; Xie
et al., 2004). Thymidine-induced stalls are known to result in
replication intermediates that involve gH2AX recruitment (Bol-
derson et al., 2004; Liu and Lim, 2005; Lundin et al., 2002;
Saleh-Gohari et al., 2005; Xie et al., 2004), and gH2AX foci
were readily discernable in thymidine-treated TCPTP-deficient
and -reconstituted cells (data not shown). Therefore, one
possibility is that the gH2AX-positive lagging chromosomes
in TCPTP-deficient cells may have resulted from unresolved
replication intermediates.
We also tested the response of TCPTP-deficient cells to aphi-
dicolin and another widely used replication inhibitor, hydroxy-
urea. Although PTK pathways were elevated in TCPTP-deficient
cells when compared to TCPTP-reconstituted cells treated with
aphidicolin, TCPTP-deficient cells remained arrested in S phase
and did not progress into G2 (data not shown). Similarly, we
found that TCPTP-deficient cells did not bypass the checkpoint
induced by hydroxyurea (data not shown), which inhibits ribonu-
cleotide reductase to deplete all cellular deoxyribonucleotide
triphosphates (thymidine only depletes deoxycytidine triphos-
phate). Previous studies have established that stalls induced
by aphidicolin and hydroxyurea can collapse to form DSBs
(Lundin et al., 2002; Rothkamm et al., 2003; Saintigny et al.,
2001). In contrast, thymidine-induced stalls do not result in
DSBs (Lundin et al., 2002). Given that DNA damage signaling
pathways and responses may not be altered in the absence of
TCPTP (Figure 1A; data not shown), we reasoned that the inabil-
ity of TCPTP-deficient cells to bypass the aphidicolin-induced
checkpoint might be due to the DSB-associated activation of
ATM signaling pathways. To test this, we determined whether
the inhibition of ATM signaling might permit aphidicolin-treated
TCPTP-deficient cells to bypass S phase and progress into
G2/M. To this end, we inhibited the ATM and ATR targets(D) G0-synchronized and released R5 cells were treated with methyl methanesulfonate (MMS; 0.0075%) as indicated, and lysates were processed for immuno-
blot analysis.
(E) G0-synchronized R5 cells were released for 11 hr, synchronized at G1/S with thymidine (2 mM) for 9 hr, and then released again and either left untreated or
exposed to ultraviolet light (UV) at 2 hr release. Cells were processed for flow cytometry tomonitor DNA content (2c and 4c cells are indicated) and for immunoblot
analysis.
(F) G0-synchronized and released R5 cells were treated with etoposide (25 mg/ml) as indicated and processed for flow cytometry and immunoblot analysis.
(G) G0-synchronized and released / and R5 cells were treated with thymidine (2 mM) at the indicated times and processed for immunoblot analysis.
Results are representative of three or more independent experiments in each case. The indicated timelines highlight themethod of synchronization, the cell-cycle
stage, treatments, and the collection time points for immunoblot analysis. In (A), (D), (E), and (G), the retarded electrophoretic mobility of Chk1 was used as an
indicator of phosphorylation and activation (p-Chk1). p-JAK1 and p-SFK in (B) and p-STAT3 in (G) were quantified by densitometric analysis and normalized for
actin or STAT3; values are given in arbitrary units (AU) as means ± SEM (significance values determined using Student’s t test: *p < 0.05, **p < 0.01).Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc. 169
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STAT3 and the Replication CheckpointFigure 2. The DNA Replication Checkpoint Response Is Defective in TCPTP-Deficient Cells
(A and B) G0-synchronized and released / and TCPTP-reconstituted MEFs (clones R5, R10, and R20) were treated with thymidine (2 mM) for the indicated
times and processed for flow cytometry (2c and 4c cells are indicated; 4c cells were quantified and means ± SEM of three independent experiments are shown;
*p < 0.05, **p < 0.01).
(C) G0-synchronized and released/ and R5 cells were treated with thymidine (2 mM) for the indicated times. Lysates were processed for immunoblotting with
antibodies to cyclin B1 (expression highest in metaphase of mitosis) and actin.
(D) G0-synchronized and released / and TCPTP-reconstituted MEFs (clones R5 and R20) were treated with thymidine (2 mM) for the indicated times and
processed for flow cytometry (4c MPM-2-positive cells were quantified and means ± SEM of three independent experiments are shown; *p < 0.05, **p < 0.01).
(E and F) G0-synchronized and released/ and R5 cells were treated with thymidine (2 mM) for 24 hr and processed for immunofluorescence microscopy after
staining for DNA (Hoechst) and either phosphorylated (Ser10) histone H3 (p-histone H3; occurs in prophase) or tubulin.
(G) G0-synchronized and released / and R5 cells were treated with aphidicolin (0.5 mM) or etoposide (25 mg/ml) for 12 hr, at which point vehicle control or
Go¨6976 (30 nM) was added and cells were processed for flow cytometry.
Results shown are representative of three independent experiments.Chk1 andChk2with the pharmacological inhibitor Go¨6976 (Kohn
et al., 2003). Consistent with our supposition, we found that
Go¨6976-treated TCPTP-deficient MEFs, otherwise arrested in
S phase by the replication inhibitor aphidicolin, progressed into
G2/M and thereon into G1 of the next cell cycle (Figure 2G). In
contrast, Go¨6976 did not abrogate the checkpoint response
and the suppression of S phase progression induced by aphidi-
colin in TCPTP-reconstituted cells but allowed TCPTP-reconsti-
tuted cells arrested in G1 and S with the DNA-damaging agent
etoposide to progress into S and G2, respectively (Figure 2G).
Thus, neither deficiencies in ATM/ATR signaling nor TCPTP are
in themselves sufficient to abrogate the aphidicolin-induced ar-
rest; instead, both ATM/ATR inactivation and sustained PTK sig-
naling are necessary for checkpoint bypass. Accordingly, we
propose that TCPTP/PTK pathways act in concert with ATM/170 Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc.ATR to coordinate the suppression of S phase progression in re-
sponse to replication stress.
ATR Antagonizes TCPTP
Our results indicated that ATM/ATR pathways are not required
for the TCPTP-mediated suppression of S phase progression:
neither pharmacological inhibition of ATM/ATR (with caffeine)
or Chk1 (with Go¨6976) nor deficiencies in ATR (short hairpin
RNA [shRNA]-mediated ATR knockdown) or ATM (ataxia-telan-
giectasia fibroblasts) allowed cells to bypass the replication
checkpoint induced by thymidine or aphidicolin, but they readily
abrogated the DNA damage checkpoint instigated by etoposide
(data not shown). Consistent with this, we found that ATM/
ATR inhibition with caffeine (Figure 4A) or Chk inhibition with
Go¨6976 (Figure 4B) did not prevent the suppression of PTKs
Cancer Cell
STAT3 and the Replication Checkpointand STAT3 in TCPTP-reconstituted cells in response to thymi-
dine. On the contrary, we found that the inhibition of ATM/ATR
signaling with caffeine or Go¨6976 resulted in a more immediate
and pronounced suppression of PTK signaling in TCPTP-re-
constituted cells (Figures 4A and 4B), suggesting that ATM/
ATR may antagonize TCPTP to prevent the complete inactiva-
tion of PTK signaling when the checkpoint is first instigated. Im-
portantly, caffeine did not promote the suppression of STAT3
signaling in TCPTP-reconstituted cells treated with the DNA-
damaging agent etoposide (data not shown). Thus, the effects
of caffeine on PTK pathway suppression may be specific to the
replication checkpoint. In addition, caffeine had no effect on
STAT3 signaling in TCPTP-deficient cells treated with thymidine
(Figure 4C), indicating that TCPTP is required for the suppres-
sion of PTK signaling after ATM/ATR inhibition. Finally, shRNA-
mediated ATR knockdown in TCPTP-reconstituted cells
enhanced the suppression of STAT3 signaling in response to
thymidine (Figure 4D), providing a link between ATR and the
Figure 3. TCPTP-Deficient Cells that Have
Bypassed the Replication Checkpoint
Exhibit Lagging Chromosomes
Asynchronous / MEFs or G0-synchronized
/ MEFs released into the cell cycle for 12 hr
and treated with thymidine (2 mM) for 24 hr were
processed for immunofluorescence microscopy
and stained for DNA (Hoechst) and either tubulin
or gH2AX as indicated.
(A) Mitotic figures were scored for lagging chromo-
somes inmetaphase, anaphase,and telophaseand
for amplified centrosomes as assessed by the
presence of asymmetric mitotic spindles. Results
are shown as means ± SEM of three independent
experiments counting 300–500 cells in each case.
(B and C) Compressed deconvolved (inverse filter)
Z stacks depicting cells with lagging chromo-
somes (white arrows).
status of PTK signaling during replication
stress. Taken together, these results
indicate that ATR specifically antago-
nizes TCPTP to coordinate the timing
and degree of PTK pathway inactivation in response to replica-
tion stress.
PTK Signaling Is Required for DNA Replication
Checkpoint Bypass
Next we determined whether the elevated PTK signaling in
TCPTP-deficient cells was responsible for the replication check-
point bypassand subsequentmitotic progression.Wedelineated
the specific contributions of the JAK PTKs and STAT3 using RNA
interference (RNAi) and asked whether the stable knockdown of
JAK1, JAK2, or STAT3 with shRNAs could prevent S phase
progression in the presence of thymidine. Suppression of JAK1
protein levels in TCPTP-deficient cells with two different JAK1-
specific shRNAs suppressed STAT3 phosphorylation and largely
prevented the replication checkpoint bypass (Figure 5A; data not
shown). In contrast, the suppression of JAK2 had no significant
effect on STAT3 phosphorylation or S phase progression (data
not shown). Consistent with this, we found that the inhibition of
Figure 4. ATR Antagonizes the TCPTP-
Mediated Suppression of PTK Signaling
(A–C) G0-synchronized and released TCPTP-
reconstituted MEFs (R5) (A and B) or / MEFs
(C) were treated with thymidine (2 mM) for 12 hr,
caffeine (2 mM) or the Chk1 inhibitor Go¨6976
(30 nM) was added, and the incubations were con-
tinued. Cells were collected at the indicated times
and processed for immunoblot analysis.
(D) G0-synchronized TCPTP-reconstituted MEFs
(R5) stably transduced with ATR shRNA lentiviral
particles were released for 12 hr, treated with
thymidine (2 mM), and processed for immunoblot
analysis.
Results shown are representative of three inde-
pendent experiments.Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc. 171
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STAT3 and the Replication CheckpointFigure 5. Elevated STAT3 Signaling Is Required for DNA Replication Checkpoint Bypass
(A and B) / MEFs were transduced with control and either JAK1 (A) or STAT3 (B) shRNA lentiviral particles. G0-synchronized cells were released for 10 hr,
treated with thymidine (2 mM), and processed for immunoblot analysis or flow cytometry.
(C) / MEFs were released into the cell cycle for 6 hr, treated with thymidine and vehicle control or the SFK inhibitor SU6656 (10 mM), and processed for
immunoblot analysis or flow cytometry (2c and 4c cells are indicated).
(D) Asynchronous U87MG cells or those expressing the 45 kDa TCPTP (TC45) were treated with thymidine and processed for immunoblot analysis or flow
cytometry at the indicated times.
Results shown are representative of at least three independent experiments. In (A)–(C), cells with a 4c DNA content were quantified at the indicated times, and
means ± SEM are shown (significance values determined using Student’s t test: *p < 0.05, **p < 0.001).JAK PTKs and downstream STAT3 signaling prior to or during S
phase with the JAK-selective inhibitor CMP6 (Thompson et al.,
2002) also suppressed replication checkpoint bypass (Figures
S5A–S5C). Furthermore, we found that the knockdown of
STAT3 with specific shRNAs prevented progression through S
phase in the presence of thymidine (Figure 5B; Figure S5D). Nei-
ther JAK1 knockdown nor STAT3 knockdown had any significant
effect on normal G1 or S phase progression in TCPTP-deficient
cells (data not shown). Therefore, these results indicate that
enhanced JAK1/STAT3 signaling may be essential for the DNA
replication checkpoint bypass in TCPTP-deficient cells.
To assess whether sustained SFK signaling may also contrib-
ute to the abrogated checkpoint response, G0-synchronized
TCPTP-deficient cellswere released intoG1and treatedwith thy-
midine with or without the SFK inhibitor SU6656 (Blake et al.,
2000), a 10 mM concentration of which was necessary for the in-
activation of SFKs in TCPTP-deficient MEFs (data not shown).
Addition of SU6656 at 6 hr release so that SFKs were inhibited
by the time the cells reached S phase (15–18 hr release) delayed
G1progression asexpectedbut alsogradually accumulatedcells
in early S phase in the presence of thymidine (Figure 5C); this was
accompanied by the suppression of STAT3 phosphorylation. Ad-172 Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc.dition of SU6656 at 15 hr release so that SFKswere inhibited after
the majority of TCPTP-deficient cells had already traversed S
phase accumulated cells in G2 (4c DNA content) and prevented
mitotic entry (Figure S6). Thus, these results are consistent with
sustained SFK signaling contributing to the replication check-
point bypass and the subsequent progression into mitosis.
Next,we sought to establish an independentmodel bywhich to
assess the impact of tyrosine phosphorylation-dependent signal-
ing on the DNA replication checkpoint. Human U87MG glioblas-
toma cells have inactivated PTEN and INK4a/ARF and also over-
express IL-6 to promote constitutive JAK/STAT3 signaling
(Goswami et al., 1998; Lee et al., 2000; Li et al., 1997). In addition,
U87MGcells express theendoplasmic reticulum-targeted48kDa
TCPTPvariant, but not the 45 kDa form (Figure 5D) that shuttles in
and out of the nucleus to dephosphorylate both cytoplasmic and
nuclear substrates such as STAT3 (Tiganis and Bennett, 2007).
Therefore, onemay expect that these cells should readily bypass
the replication checkpoint. Consistent with this, we found that al-
though the progression of asynchronous cellswas somewhat de-
layed by thymidine, U87MG bypassed the thymidine-induced S
phase arrest and proceeded into G2/M and subsequently G1 of
the next cell cycle (Figure 5D). The replication checkpoint bypass
Cancer Cell
STAT3 and the Replication CheckpointFigure 6. Sustained STAT3-Mediated Cyclin D1 Expression in TCPTP-Deficient Cells
(A and B) G0-synchronized / and TCPTP-reconstituted MEFs (R5) were released into the cell cycle for 12 hr, treated with thymidine (2 mM) or aphidicolin
(2 mM), and processed for immunoblot analysis. In (A), cyclin D1 in R5 cells was quantified by densitometric analysis and normalized for tubulin; data are given
in arbitrary units (AU) as means ± SEM of three independent experiments.
(C) G0-synchronized /MEFs were released into the cell cycle for 12 hr, treated with thymidine and then with either vehicle control or the JAK inhibitor CMP6
(5 mM) at the equivalent of 15 or 18 hr release, and processed for immunoblot analysis at the indicated times.
(D) G0-synchronized/MEFs transduced with either control or STAT3-specific shRNA lentiviral particles were released into the cell cycle for 12 hr, treated with
thymidine (2 mM), and processed for immunoblot analysis.
Results shown are representative of at least three independent experiments.was delayed by the pharmacological inhibition of the SFK or JAK
PTKs and the consequent suppression of STAT3 (data not
shown). Furthermore, stable expression of the 45 kDa TCPTP
form resulted in the suppression of SFK and STAT3 signaling
and prevented the replication checkpoint bypass, maintaining
U87MG cells arrested in S phase (Figure 5D); TCPTP expression
did not alter the cell-cycle progression (Figure 5D) or proliferation
in untreated cells (Klingler-Hoffmann et al., 2001). These results
are consistent with TCPTP-regulated PTK pathways being
specifically linked to the DNA replication checkpoint.
STAT3-Induced Cyclin D1 Is Required for DNA
Replication Checkpoint Bypass
Our studies indicate that the regulation of STAT3 is integral to the
DNA replication checkpoint response. A key STAT3 transcrip-
tional target is CCND1, which encodes cyclin D1 (Bromberg
et al., 1999; Fukada et al., 1998). Cyclin D1 is an allosteric regu-
lator of CDK4/6 and promotes G1/S progression through the
CDK4/6-mediated phosphorylation and inactivation of the reti-
noblastoma protein (pRb) (Sherr, 1995). We found that cyclin
D1 protein declined in TCPTP-reconstituted cells treated with
either thymidine (Figure 6A) or aphidicolin (data not shown) to al-
most negligible levels by 24–36 hr of treatment. As expected, the
decline of cyclin D1 in thymidine-treated cells was associated
with a decrease in pRb phosphorylation on the CDK4 target
site Ser807/Ser811 (Figure S7). In marked contrast, cyclin D1 ex-
pression (Figure 6A) and pRb phosphorylation (Figure S7) were
sustained in TCPTP-deficient cells treated with thymidine.
Recent studies have reported that the nuclear accumulation of
a cancer-derived oncogenic cyclin D1 mutant during S phasecan inhibit the proteolysis of the origin licensing factor Cdt1, re-
sulting in rereplication (Aggarwal et al., 2007). In line with the
maintenance of cyclin D1 and sustained pRb phosphorylation,
we found that Cdt1 levels were also elevated in TCPTP-deficient
cells (Figure 6B). Notably, we found that the maintenance of cy-
clin D1 protein in thymidine-treated TCPTP-deficient cells was
attributable to the sustained/elevated PTK/STAT3 signaling,
since pharmacological inhibition of the SFK (data not shown)
or JAK PTKs during S phase (at the equivalent of 15 or 18 hr re-
lease) and the consequent suppression of STAT3 (Figure 6C;
Figure S5C) or the knockdown of STAT3 by RNAi resulted in
the replication checkpoint-induced depletion of cyclin D1 with-
out altering cyclin D1 levels in untreated cells in G1 (0 hr thymi-
dine, Figure 6D; data not shown). Therefore, these results sug-
gest that sustained STAT3 signaling and checkpoint bypass
might be associated with the maintenance of cyclin D1 levels
in S phase.
Previous studies have reported that cyclin D1 accumulates in
G1, plateaus in S, and then increases again in G2 (Baldin et al.,
1993; Guo et al., 2005; Hitomi and Stacey, 1999; Pagano et al.,
1994). Furthermore, cyclin D1 has been shown translocate
from the nucleus to the cytoplasm during S phase so that it is se-
questered away from nuclear substrates and is degraded (Baldin
et al., 1993; Guo et al., 2005; Hitomi and Stacey, 1999; Pagano
et al., 1994). This prompted us to examine the levels and subcel-
lular localization of cyclin D1 in normal S phase and under
conditions of replication stress in more detail. First, cyclin D1
levels were examined in cells proceeding through S phase. In
G0-synchronized and released MEFs, cyclin D1 increased from
12 hr (G1) to 15 hr (G1/S) release and then remained constantCancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc. 173
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(A and B) G0-synchronized TCPTP-reconstituted MEFs (R5) were released (Rel) into the cell cycle, either left untreated or treated with MMS (0.0075%) at 15 or
18 hr release, and processed for immunoblot analysis (A) or immunofluorescence microscopy with cyclin D1-specific antibodies (B) at the indicated times.
(C and D) G0-synchronized R5 cells were released for 12 hr, treated with thymidine (Thy; 2 mM) for 6 hr to synchronize cells at G1/S, and then released and left
untreated or treated at 2 hr release with MMS (0.0075%) or UV for the indicated times. Cells were processed for immunoblot analysis, DNA content analysis by
flow cytometry (2c and 4c cells indicated), or immunofluorescence microscopy (S phase cells identified by the incorporation of BrdU) as indicated.
Results shown are representative of three independent experiments in each case. In (C), S phase entry (>2c <4c) of untreated cells was quantified for three
independent experiments, and means ± SEM are shown.until cells entered G2 at 24–27 hr (Figure 7A). In MEFs released
from G0, synchronized briefly at G1/S with thymidine, and then
released back into S phase (so that >50% were in S phase by
4 hr release; Figure 7C), we noted an apparent decline in cyclin
D1 protein after thymidine synchronization and an increase after
release into S phase; the increase in cyclin D1 occurred prior to
G2 onset (Figure 7C; Figure S8). By immunofluorescence mi-
croscopy, we noted that nuclear cyclin D1 was highest at the
G1/S transition (15 hr release) and was reduced but nevertheless
present in the nuclei of S phase cells (18 hr release) (Figure 7B)
incorporating bromodeoxyuridine (BrdU) (data not shown). Sim-
ilarly, nuclear cyclin D1 was evident in cells that were G1/S syn-
chronized (treated at 12 hr release with thymidine for 6 hr) and
released for 2–4 hr into S phase (prior to G2 onset; Figure 7C).
Thus, these results indicate that cyclin D1 protein is present in
S phase cells and that at least some of this protein persists in
the nuclei of cells replicating DNA. Next, we determined the im-
pact of replication stress on cyclin D1 levels and localization. G0-
synchronized and released MEFs or cells synchronized at G1/S
by brief thymidine treatment and released back into S phase
were exposed to replication inhibitors. Treatment of cells at
G1/S (15 hr release) or during S phase (18 hr release)
(Figure 7A) or cells synchronized at G1/S (with brief thymidine
treatment) and released back into S phase with MMS
(Figure 7C; data not shown) or UV (Figure 1E; Figure 7D;
Figure S3) resulted in the inactivation of STAT3 and concomitant
depletion of cyclin D1. Importantly, treatment with MMS com-
pletely eliminated cyclin D1 from the nucleus in S phase cells
(Figure 7C). Taken together, these results indicate that nuclear174 Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc.cyclin D1 is present during S phase, albeit at considerably lower
levels than those found in late G1, and that replication stress
results in its rapid elimination.
Having established that cyclin D1 is present in S phase nuclei
and that it is eliminated by replication stress, we next determined
whether sustained nuclear cyclin D1 may be responsible for the
checkpoint bypass of TCPTP-deficient cells. The biochemical
activity of cyclin D1 is mediated by its interaction with CDK4/6
in the nucleus (Sherr, 1995). Accordingly, we determinedwhether
the CDK4-selective pharmacological inhibitor R00505124-000
(CDK4i) (Burgess et al., 2006) could prevent S phase progres-
sion in the presence of thymidine. CDK4i (1–2 mM) suppressed
pRb phosphorylation on the CDK4 target site Ser807/Ser811
and inhibited the replication checkpoint bypass irrespective of
whether CDK4i was added prior to (Figure 8A) or at the onset
of S phase (Figure S9). We also asked whether promoting cyclin
D1 degradation could prevent the replication checkpoint bypass
of TCPTP-deficient cells. Inhibition of PI3K/Akt signaling targets
cyclin D1 for proteasomal degradation (Diehl et al., 1998). We
found that the PI3K inhibitor wortmannin reduced cyclin D1 pro-
tein levels and suppressed S phase progression in thymidine-
treated TCPTP-deficient cells (Figure S10). Furthermore, the
knockdown of cyclin D1 with two different cyclin D1-specific
shRNAs prevented the replication checkpoint bypass of
TCPTP-deficient cells (Figure 8B) without having any overt effect
on normal G1/S progression (Figure S11). Finally, we asked
whether preventing the decline in cyclin D1 in response to repli-
cation stress could promote replication checkpoint bypass in
TCPTP-reconstituted cells. To this end, we asked whether
Cancer Cell
STAT3 and the Replication CheckpointFigure 8. Sustained Cyclin D1 Expression Is Necessary for Replication Checkpoint Bypass
(A) G0-synchronized /MEFs were released into the cell cycle for 12 hr, treated with thymidine (2 mM) and either vehicle control (DMSO) or a CDK4 inhibitor
(CDK4i; 2 mM), and processed for flow cytometry and immunoblot analysis.
(B) G0-synchronized / MEFs stably transduced with cyclin D1-specific shRNAs were released for 12 hr, treated with thymidine, and processed for flow
cytometry and immunoblot analysis at the indicated times.
(C) R5 MEFs were released into the cell cycle, treated with thymidine (Thy) and then MG132 (5 mM) at the indicated times, and processed for flow cytometry and
immunoblot analysis.
(D and E) HeLa cells transduced stably with control or TCPTP shRNAswere synchronized by double thymidine block, released and treated with thymidine (1 mM)
as indicated, and collected for flow cytometry (D) and immunoblot (E) analysis.
Results shown are representative of three independent experiments in (A) and (C)–(E) and two independent experiments in (B).blocking the degradation of cyclin D1 in TCPTP-reconstituted
cells with the proteasome inhibitor MG132 could promote repli-
cation checkpoint bypass. Addition of MG132 at 6 hr thymidine
treatment (equivalent to 18 hr release) increased the overall
levels of cyclin D1 and promoted the progression of thymi-
dine-treated TCPTP-reconstituted cells through S phase, with
some cells progressing into G2/M (Figure 8C). Taken together,
these results are consistent with the regulation of cyclin D1 ex-
pression and stability being integral to the DNA replication
checkpoint response.
One possibility is that sustained cyclin D1-CDK4 activity and
the subsequent sustained phosphorylation and inactivation of
pRb in TCPTP-deficient cells may be responsible for the repli-
cation checkpoint bypass. To examine this directly, we asked
whether the shRNA-mediated knockdown of pRb in TCPTP-
reconstituted cells could compromise the integrity of the
DNA replication checkpoint and allow TCPTP-reconstituted
cells to progress into G2. Stable suppression of pRb protein
levels by as much as 80% did not abrogate the checkpoint
response (Figure S12). Consistent with this, we found thatthe replication checkpoint was largely intact in HeLa cells
(Figure 8D; data not shown), in which pRb-family pocket pro-
teins are inactivated by the papillomavirus E7 oncoprotein.
As in fibroblasts, we found that cyclin D1 protein declined in
thymidine-treated HeLa cells (Figure 8E). Taken together, these
results indicate that the replication checkpoint may be regu-
lated by cyclin D1-CDK4 independently of pRb. Consistent
with this, we found that the shRNA-mediated suppression of
TCPTP in HeLa cells resulted in elevated SFK and STAT3 sig-
naling (Figure S13; data not shown), sustained cyclin D1 pro-
tein levels, and bypass of the thymidine-induced replication
checkpoint (Figures 8D and 8E; data not shown). Importantly,
S phase progression per se was not altered in HeLa cells after
TCPTP knockdown (Figure S13), indicating that the bypass
was not simply due to enhanced G1 or S progression. Thus,
these results affirm TCPTP’s role in the cell-cycle-dependent
regulation of SFK and STAT3 signaling and in the specific reg-
ulation of the DNA replication checkpoint response by tyrosine
phosphorylation and cyclin D1-dependent but pRb-indepen-
dent pathways.Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc. 175
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Given the complexity and scale of DNA replication, it is not sur-
prising that complex S phase checkpoint mechanisms have
evolved to ensure that this process occurs accurately and in
a timely manner (Bartek et al., 2004). In this study, we have
shown that the JAK and SFK PTKs and their target STAT3 are at-
tenuated specifically in response to stalls in DNA replication to
coordinately suppress S phase and mitotic progression. Specif-
ically, our studies show that the attenuation of STAT3-mediated
cyclin D1 transcription allows for proteasome-mediated deple-
tion of cyclin D1 to facilitate the suppression of S phase progres-
sion. We found that TCPTP was essential for the suppression of
the SFK and JAK PTKs and STAT3 in response to stalls caused
by thymidine or aphidicolin. Importantly, in TCPTP-deficient
MEFs, STAT3 phosphorylation increased significantly in re-
sponse to thymidine or aphidicolin, with similar albeit slightly
delayed kinetics to the induction of the ATR-instigated Chk1-
mediated checkpoint. Therefore, we propose that TCPTP is re-
quired upon replication fork stalling to prevent STAT3 hyperacti-
vation and the associated checkpoint bypass. Although TCPTP
can suppress STAT3 signaling by inactivating the SFK and JAK
PTKs, previous studies have reported that TCPTP can also act
directly on STAT family members (Lu et al., 2007; Tiganis and
Bennett, 2007), including STAT3 (Yamamoto et al., 2002). There-
fore, it is possible that TCPTP might act both directly and
indirectly to inactivate STAT3 upon replication stress.
The degree and timing of PTK pathway inactivation in TCPTP-
expressing cells varied depending on the replication stress. The
response to thymidine or aphidicolin was biphasic, with STAT3
signaling being at first attenuated and then inactivated.We found
that the control of PTK signaling in response to thymidine or
aphidicolin, which slow fork progression and may for example
mimic the response to fragile sites or slow replication zones
(Glover et al., 1984; Lemoine et al., 2005), was mediated by
TCPTP with the biphasic nature being ascribed to the antagonis-
tic regulation by ATR. We showed that TCPTP prevented STAT3
hyperactivation and the associated checkpoint bypass early in
the response to replication stress but that ATR antagonized
the complete inactivation of STAT3 by TCPTP. This raises the
question as to why it may be necessary to prevent the complete
inactivation of STAT3. Although further studies are needed to
address this, we propose that the maintenance of STAT3 signal-
ing may facilitate recovery after replication stress is alleviated,
since S phase progression was compromised in TCPTP-recon-
stituted but not -deficient cells released from prolonged thymi-
dine treatment (unpublished data). Our studies indicate that the
trigger for the complete inactivation of PTK signaling by TCPTP
is the waning of ATR/Chk1 signaling (occurring when the cells
would otherwise exit S phase; see Figure 1G). In Xenopus,
Chk1 inactivation resulting from the degradation of claspin may
be associated with the adaptation of cells from the DNA replica-
tion checkpoint (Yoo et al., 2004), whereas in mammalian cells,
claspin degradation may be required for recovery when replica-
tion/genotoxic stresses are removed (Mailand et al., 2006;
Peschiaroli et al., 2006). In our experiments, we found that
MEFs remained arrested in S phase long after the thymidine-
or aphidicolin-induced activation of Chk1 subsided. Therefore,
we propose that PTK pathway inactivation when ATR/Chk1 sig-176 Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc.naling subsides may be critical to the maintenance of S phase
arrest under conditions of prolonged replicative stress that result
in the accumulation of replication intermediates and damaged
DNA.
MMS and UV, which modify DNA to directly stall replication
forks, caused the immediate and complete inactivation of PTK
signaling upon S phase entry, independent of TCPTP status,
and this coincided with the induction of ATR/Chk1 checkpoint
signaling. Thus, DNA damage specifically at replication forks
may be the trigger for an overriding TCPTP-independent path-
way for the suppression of PTK signaling. Consistent with this
notion, we found that after prolonged treatment with aphidicolin
(which collapses forks to generate DSBs), PTK signaling was
also attenuated in TCPTP-deficient cells, albeit remaining ele-
vated when compared to TCPTP-reconstituted cells at the
same time points; the suppression of PTK signaling at these later
time points coincided with the activation of ATM. Thus, we pro-
pose that the suppression of PTK signaling may work in concert
with DNA damage response pathways activated at stalled or
damaged replication forks to suppress S phase progression. In
line with this, we found that inhibiting ATM/ATR signaling permit-
ted aphidicolin-treated TCPTP-deficient cells, but not TCPTP-
reconstituted cells, otherwise arrested in S phase, to bypass
the checkpoint and progress into G2/M.
Our studies indicate that the coordination of cyclin D1 produc-
tion and degradation may be integral to the DNA replication
checkpoint response and that failure to eliminate cyclin D1 due
to sustained STAT3-mediated transcriptionmay allow for check-
point bypass. Previous studies have shown that nuclear cyclin
D1 is reduced in S phase, and this has been attributed to nuclear
exit and degradation (Baldin et al., 1993; Guo et al., 2005; Hitomi
and Stacey, 1999; Pagano et al., 1994). In our studies, we found
that, although reduced, nuclear cyclin D1 continued to be pres-
ent in S phase cells coinciding with incorporated BrdU; nuclear
cyclin D1 was also noted in MRC5 and IMR90 fibroblasts during
S phase (unpublished data). Thus, although high levels of nuclear
cyclin D1 may be deleterious to DNA replication and repair (Pa-
gano et al., 1994), we surmise that low levels of cyclin D1 might
continue to be necessary in the nuclei of S phase cells. Previous
studies have shown that cyclin D1 can be degraded in response
to UV-, g irradiation-, or cisplatin-mediated DNA damage in
MEFs, human fibroblasts, and HeLa cells and that this may be
essential for DNA repair (Agami and Bernards, 2000; Lan et al.,
2002; Pagano et al., 1994). Notably, the g irradiation-instigated
reduction in cyclin D1 has been shown to precede the activation
of p53 and to be essential for the induction of G1 arrest (Agami
and Bernards, 2000). Our studies show that the depletion of cy-
clin D1 may also be integral to the DNA replication checkpoint
and that this may be reliant not only on instigated degradation
but also on the suppression of STAT3-mediated cyclin D1 ex-
pression.
Recent studies have shown that hyperplasia and premature
origin firing associated with the expression of oncoproteins
such as c-Mos, cyclin E, or activated STAT5 can result in replica-
tion-associated damage and the activation of DNA damage
checkpoints in normal fibroblasts as well as U2OS osteosar-
coma cells (Bartkova et al., 2005, 2006; Di Micco et al., 2006;
Mallette et al., 2007). The activation of DNA damage checkpoint
pathways in precancerous lesions consequently promotes
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promised, genomic instability and senescence bypass ensue,
resulting in tumorigenesis (Bartkova et al., 2005, 2006; Collado
et al., 2005; Di Micco et al., 2006; Gorgoulis et al., 2005; Mallette
et al., 2007). In our studies, we saw no evidence for the inappro-
priate activation of DNA damage checkpoint pathways. How-
ever, overall proliferation and S phase progression were not
increased in TCPTP-deficient cells. Therefore, the activation of
oncogenic PTKs per se may not be sufficient to instigate DNA
damage checkpoints and associated senescence, at least not
without first inducing hyperproliferation. Thus, our studies pro-
vide insight into an alternative means by which oncogenic PTK
pathways may contribute to tumorigenesis.
The aberrant activation of PTK signaling in tumor cells confers
selective growth advantages that include increased proliferation
and survival. However, information as to the involvement of spe-
cific PTPs in tumorigenesis has only recently started to emerge
(Bentires-Alj et al., 2004; Julien et al., 2007). In the case of
TCPTP, although polymorphisms in Ptpn2 have been linked
with the development of several inflammatory disorders
(WTCCC, 2007; Todd et al., 2007), similar polymorphisms or mu-
tations have not been identified in human tumors. However, we
have shown previously that the downregulation of TCPTP can
contribute to the resistance of CML cells to the ABL inhibitor
STI571 in vitro (Shimizu et al., 2004), whereas differences in
TCPTP expression may contribute to the distinct biological char-
acteristics of diffuse large B cell lymphoma subtypes (Lu et al.,
2007). In addition, TCPTP is expressed to varying degrees in
breast cancer cell lines (unpublished data). Therefore, it is possi-
ble that TCPTP deficiency may contribute to tumorigenicity by
abrogating the replication checkpoint. Nevertheless, irrespec-
tive of TCPTP status, the results of this study highlight the poten-
tial for oncogenic PTK pathways to perturb the replication
checkpoint response and contribute to genomic instability and
tumor progression.
EXPERIMENTAL PROCEDURES
Reagents
CMP6 (2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquino-
line-7-one), aphidicolin, Go¨6976, thymidine, and anti-v-Src were from Calbio-
chem; SU6656, etoposide,MMS,MG132, wortmannin, and caffeine were from
Sigma-Aldrich; adriamycin was from ICN; p53, phospho (p)-p53 (Ser15),
p-STAT3 (Tyr705), p-SFK (Tyr418), p-ATM (Ser1981), p-SFK (Tyr418), Chk1,
and STAT3 antibodies were from Cell Signaling; JAK1, JAK2, Cdt1, Cyclin
D1, and ATR antibodies were from Santa Cruz; p-SFK (Tyr418) and p-JAK1
(Tyr1022/Tyr1023) were from Biosource; cyclin B1 and D1 antibodies were
from BD Biosciences; and p-histone H3 (Ser10) and MPM-2 antibodies were
from Upstate. The CDK4 inhibitor RO0505124 was provided by Hoffmann-
La Roche Inc., anti-TCPTP CF4 was provided by N.K. Tonks (Cold Spring Har-
bor Laboratory), anti-gH2AXwas provided by J. Heierhorst (St. Vincent’s Insti-
tute), and Ptpn2/ cells were provided by M.L. Tremblay (McGill University).
Cell Culture
Generation and culture conditions of spontaneously immortalized Ptpn2/
MEFs and those reconstituted with the 45 kDa form of TCPTP (clones R5,
R10, and R20) (Galic et al., 2003; Ibarra-Sanchez et al., 2001), U87MG cells
and those expressing TCPTP, and HeLa cells were as described previously
(Klingler-Hoffmann et al., 2001). For G0 synchronization, MEFs were seeded
at 0.5–1.0 3 106 cells per 10 cm dish and cultured for 48 hr, serum starved
in medium containing 0.1% (v/v) FBS for 48 hr, and released into the cell cycle
by readdition of FBS. For stable knockdown, control (MISSION pLKO.1-Purocontrol particles) and STAT3 (#1: ID71455; #2: ID71457; #3: ID71453), ATR
(#1: ID23909; #2: ID23910; #3: ID23911; #4: ID23912; #5: ID23913), JAK1
(#1: ID23289; #2: ID23290), TCPTP (ID2783), or cyclin D1 (#1: ID55233; #2:
ID55236) specific shRNA lentiviral particles (Sigma-Aldrich) were used to
transduce Ptpn2/ immortalized MEFs, TCPTP-reconstituted MEFs, or
HeLa cells according to the manufacturer’s instructions, and cells were
selected in 2 mg/ml puromycin.
Microscopy and Flow Cytometry
Cells were fixedwith 95% (v/v) ethanol, and fluorescence-activated cell sorting
analysis was performed on propidium iodide-stained cells; where indicated,
cells were also stained with MPM-2. Immunofluorescence microscopy was
performed as described previously (Tiganis et al., 1998) using a Zeiss Axioskop
2mot plusmicroscope and Zeiss AxioVision software. BrdU incorporation was
assayed using a kit (Roche) according to the manufacturer’s instructions.
Statistical Analysis
A one-tailed Student’s t test was used to test for differences between geno-
types or treatments.
SUPPLEMENTAL DATA
The Supplemental Data include thirteen figures and can be found with this
article online at http://www.cancercell.org/cgi/content/full/14/2/166/DC1/.
ACKNOWLEDGMENTS
We thank J. Heierhorst, B. Gabrielli, and K.K. Khanna for helpful discussions.
This work was supported by the National Health and Medical Research Coun-
cil of Australia and the Cancer Council Victoria. T.T. is a National Health and
Medical Research Council Senior Research Fellow.
Received: June 7, 2007
Revised: December 17, 2007
Accepted: June 9, 2008
Published: August 11, 2008
REFERENCES
Agami, R., and Bernards, R. (2000). Distinct initiation and maintenance mech-
anisms cooperate to induce G1 cell cycle arrest in response to DNA damage.
Cell 102, 55–66.
Aggarwal, P., Lessie, M.D., Lin, D.I., Pontano, L., Gladden, A.B., Nuskey, B.,
Goradia, A., Wasik, M.A., Klein-Szanto, A.J., Rustgi, A.K., et al. (2007). Nuclear
accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1
proteolysis and triggers p53-dependent DNA rereplication. Genes Dev. 21,
2908–2922.
al-Khodairy, F., and Carr, A.M. (1992). DNA repair mutants defining G2 check-
point pathways in Schizosaccharomyces pombe. EMBO J. 11, 1343–1350.
Baldin, V., Lukas, J., Marcote, M.J., Pagano, M., and Draetta, G. (1993). Cyclin
D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7,
812–821.
Bartek, J., Lukas, C., and Lukas, J. (2004). Checking on DNA damage in
S phase. Nat. Rev. Mol. Cell Biol. 5, 792–804.
Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., Guldberg, P.,
Sehested, M., Nesland, J.M., Lukas, C., et al. (2005). DNA damage response
as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434,
864–870.
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N.,
Vassiliou, L.V., Kolettas, E., Niforou, K., Zoumpourlis, V.C., et al. (2006). Onco-
gene-induced senescence is part of the tumorigenesis barrier imposed by
DNA damage checkpoints. Nature 444, 633–637.
Bentires-Alj, M., Paez, J.G., David, F.S., Keilhack, H., Halmos, B., Naoki, K.,
Maris, J.M., Richardson, A., Bardelli, A., Sugarbaker, D.J., et al. (2004). Acti-
vating mutations of the noonan syndrome-associated SHP2/PTPN11 gene inCancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc. 177
Cancer Cell
STAT3 and the Replication Checkpointhuman solid tumors and adult acute myelogenous leukemia. Cancer Res. 64,
8816–8820.
Blake, R.A., Broome, M.A., Liu, X., Wu, J., Gishizky, M., Sun, L., and Court-
neidge, S.A. (2000). SU6656, a selective src family kinase inhibitor, used to
probe growth factor signaling. Mol. Cell. Biol. 20, 9018–9027.
Bolderson, E., Scorah, J., Helleday, T., Smythe, C., andMeuth, M. (2004). ATM
is required for the cellular response to thymidine induced replication fork
stress. Hum. Mol. Genet. 13, 2937–2945.
Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G.,
Albanese, C., and Darnell, J.E., Jr. (1999). Stat3 as an oncogene. Cell 98,
295–303.
Brown, E.J., and Baltimore, D. (2003). Essential and dispensable roles of ATR
in cell cycle arrest and genome maintenance. Genes Dev. 17, 615–628.
Burgess, A., Wigan, M., Giles, N., Depinto, W., Gillespie, P., Stevens, F., and
Gabrielli, B. (2006). Inhibition of S/G2 phase CDK4 reduces mitotic fidelity.
J. Biol. Chem. 281, 9987–9995.
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A.J., Barradas, M.,
Benguria, A., Zaballos, A., Flores, J.M., Barbacid, M., et al. (2005). Tumour
biology: senescence in premalignant tumours. Nature 436, 642.
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C.,
Schurra, C., Garre, M., Nuciforo, P.G., Bensimon, A., et al. (2006). Oncogene-
induced senescence is a DNA damage response triggered by DNA hyper-
replication. Nature 444, 638–642.
Diehl, J.A., Cheng, M., Roussel, M.F., and Sherr, C.J. (1998). Glycogen syn-
thase kinase-3beta regulates cyclin D1 proteolysis and subcellular localiza-
tion. Genes Dev. 12, 3499–3511.
Enoch, T., Carr, A.M., and Nurse, P. (1992). Fission yeast genes involved in
coupling mitosis to completion of DNA replication. Genes Dev. 6, 2035–2046.
Fukada, T., Ohtani, T., Yoshida, Y., Shirogane, T., Nishida, K., Nakajima, K.,
Hibi, M., and Hirano, T. (1998). STAT3 orchestrates contradictory signals in
cytokine-induced G1 to S cell-cycle transition. EMBO J. 17, 6670–6677.
Galic, S., Klingler-Hoffmann, M., Fodero-Tavoletti, M.T., Puryer, M.A., Meng,
T.C., Tonks, N.K., and Tiganis, T. (2003). Regulation of insulin receptor signal-
ing by the protein tyrosine phosphatase TCPTP.Mol. Cell. Biol. 23, 2096–2108.
Glover, T.W., Berger, C., Coyle, J., and Echo, B. (1984). DNA polymerase alpha
inhibition by aphidicolin induces gaps and breaks at common fragile sites in
human chromosomes. Hum. Genet. 67, 136–142.
Gorgoulis, V.G., Vassiliou, L.V., Karakaidos, P., Zacharatos, P., Kotsinas, A.,
Liloglou, T., Venere, M., Ditullio, R.A., Jr., Kastrinakis, N.G., Levy, B., et al.
(2005). Activation of the DNA damage checkpoint and genomic instability in
human precancerous lesions. Nature 434, 907–913.
Goswami, S., Gupta, A., and Sharma, S.K. (1998). Interleukin-6-mediated au-
tocrine growth promotion in human glioblastoma multiforme cell line U87MG.
J. Neurochem. 71, 1837–1845.
Guo, Y., Harwalkar, J., Stacey, D.W., and Hitomi, M. (2005). Destabilization of
cyclin D1 message plays a critical role in cell cycle exit upon mitogen with-
drawal. Oncogene 24, 1032–1042.
Hitomi, M., and Stacey, D.W. (1999). Cyclin D1 production in cycling cells
depends on ras in a cell-cycle-specific manner. Curr. Biol. 9, 1075–1084.
Ibarra-Sanchez, M.J., Wagner, J., Ong, M.T., Lampron, C., and Tremblay, M.L.
(2001). Murine embryonic fibroblasts lacking TC-PTP display delayed G1
phase through defective NF-kappaB activation. Oncogene 20, 4728–4739.
Julien, S.G., Dube, N., Read, M., Penney, J., Paquet, M., Han, Y., Kennedy,
B.P., Muller, W.J., and Tremblay, M.L. (2007). Protein tyrosine phosphatase
1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis
and protects from lung metastasis. Nat. Genet. 39, 338–346.
Kastan, M.B., andBartek, J. (2004). Cell-cycle checkpoints and cancer. Nature
432, 316–323.
Klingler-Hoffmann, M., Fodero-Tavoletti, M.T., Mishima, K., Narita, Y., Cave-
nee, W.K., Furnari, F.B., Huang, H.J., and Tiganis, T. (2001). The protein tyro-
sine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells
expressing a mutant epidermal growth factor receptor. J. Biol. Chem. 276,
46313–46318.178 Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc.Kohn, E.A., Yoo, C.J., and Eastman, A. (2003). The protein kinase C inhibitor
Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle
checkpoints. Cancer Res. 63, 31–35.
Lan, Z., Sever-Chroneos, Z., Strobeck, M.W., Park, C.H., Baskaran, R., Edel-
mann, W., Leone, G., and Knudsen, E.S. (2002). DNA damage invokes mis-
match repair-dependent cyclin D1 attenuation and retinoblastoma signaling
pathways to inhibit CDK2. J. Biol. Chem. 277, 8372–8381.
Lee, S.H., Kim, M.S., Kwon, H.C., Park, I.C., Park, M.J., Lee, C.T., Kim, Y.W.,
Kim, C.M., and Hong, S.I. (2000). Growth inhibitory effect on glioma cells of ad-
enovirus-mediated p16/INK4a gene transfer in vitro and in vivo. Int. J. Mol.
Med. 6, 559–563.
Lemoine, F.J., Degtyareva, N.P., Lobachev, K., and Petes, T.D. (2005). Chro-
mosomal translocations in yeast induced by low levels of DNA polymerase
a model for chromosome fragile sites. Cell 120, 587–598.
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Milia-
resis, C., Rodgers, L., McCombie, R., et al. (1997). PTEN, a putative protein
tyrosine phosphatase gene mutated in human brain, breast, and prostate
cancer. Science 275, 1943–1947.
Liu, N., and Lim, C.S. (2005). Differential roles of XRCC2 in homologous recom-
binational repair of stalled replication forks. J. Cell. Biochem. 95, 942–954.
Lu, X., Chen, J., Sasmono, R.T., Hsi, E.D., Sarosiek, K.A., Tiganis, T., and
Lossos, I.S. (2007). T-cell protein tyrosine phosphatase, distinctively
expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the
nuclear phosphatase of STAT6. Mol. Cell. Biol. 27, 2166–2179.
Lundin, C., Erixon, K., Arnaudeau, C., Schultz, N., Jenssen, D., Meuth, M., and
Helleday, T. (2002). Different roles for nonhomologous end joining and homol-
ogous recombination following replication arrest in mammalian cells. Mol. Cell.
Biol. 22, 5869–5878.
Lundin, C., North, M., Erixon, K., Walters, K., Jenssen, D., Goldman, A.S., and
Helleday, T. (2005). Methyl methanesulfonate (MMS) produces heat-labile
DNA damage but no detectable in vivo DNA double-strand breaks. Nucleic
Acids Res. 33, 3799–3811.
Mailand, N., Bekker-Jensen, S., Bartek, J., and Lukas, J. (2006). Destruction of
Claspin by SCFßTrCP restrains Chk1 activation and facilitates recovery from
genotoxic stress. Mol. Cell 23, 307–318.
Mallette, F.A., Gaumont-Leclerc, M.F., and Ferbeyre, G. (2007). The DNA dam-
age signaling pathway is a critical mediator of oncogene-induced senescence.
Genes Dev. 21, 43–48.
Merrick, C.J., Jackson, D., and Diffley, J.F. (2004). Visualization of altered rep-
lication dynamics after DNA damage in human cells. J. Biol. Chem. 279,
20067–20075.
Osborn, A.J., Elledge, S.J., and Zou, L. (2002). Checking on the fork: the DNA-
replication stress-response pathway. Trends Cell Biol. 12, 509–516.
Pagano, M., Theodoras, A.M., Tam, S.W., and Draetta, G.F. (1994). Cyclin D1-
mediated inhibition of repair and replicative DNA synthesis in human fibro-
blasts. Genes Dev. 8, 1627–1639.
Peschiaroli, A., Dorrello, N.V., Guardavaccaro, D., Venere, M., Halazonetis, T.,
Sherman, N.E., and Pagano, M. (2006). SCFbetaTrCP-mediated degradation
of Claspin regulates recovery from the DNA replication checkpoint response.
Mol. Cell 23, 319–329.
Rothkamm, K., Kruger, I., Thompson, L.H., and Lobrich, M. (2003). Pathways
of DNA double-strand break repair during the mammalian cell cycle. Mol. Cell.
Biol. 23, 5706–5715.
Saintigny, Y., Delacote, F., Vares, G., Petitot, F., Lambert, S., Averbeck, D.,
and Lopez, B.S. (2001). Characterization of homologous recombination in-
duced by replication inhibition in mammalian cells. EMBO J. 20, 3861–3870.
Saleh-Gohari, N., Bryant, H.E., Schultz, N., Parker, K.M., Cassel, T.N., and Hel-
leday, T. (2005). Spontaneous homologous recombination is induced by col-
lapsed replication forks that are caused by endogenous DNA single-strand
breaks. Mol. Cell. Biol. 25, 7158–7169.
Sherr, C.J. (1995). D-type cyclins. Trends Biochem. Sci. 20, 187–190.
Shimizu, T., Miyakawa, Y., Iwata, S., Kuribara, A., Tiganis, T., Morimoto, C.,
Ikeda, Y., and Kizaki, M. (2004). A novel mechanism for imatinib mesylate
Cancer Cell
STAT3 and the Replication Checkpoint(STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals
downstream from the BCR-ABL fusion protein. Exp. Hematol. 32, 1057–1063.
Tanaka, T., Halicka, H.D., Traganos, F., Seiter, K., and Darzynkiewicz, Z.
(2007). Induction of ATM activation, histone H2AX phosphorylation and apo-
ptosis by etoposide: relation to cell cycle phase. Cell Cycle 6, 371–376.
Tercero, J.A., and Diffley, J.F. (2001). Regulation of DNA replication fork pro-
gression through damaged DNA by the Mec1/Rad53 checkpoint. Nature
412, 553–557.
Thompson, J.E., Cubbon, R.M., Cummings, R.T., Wicker, L.S., Frankshun, R.,
Cunningham, B.R., Cameron, P.M., Meinke, P.T., Liverton, N., Weng, Y., and
DeMartino, J.A. (2002). Photochemical preparation of a pyridone containing
tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett. 12,
1219–1223.
Tiganis, T., and Bennett, A.M. (2007). Protein tyrosine phosphatase function:
the substrate perspective. Biochem. J. 402, 1–15.
Tiganis, T., Bennett, A.M., Ravichandran, K.S., and Tonks, N.K. (1998). Epider-
mal growth factor receptor and the adaptor protein p52Shc are specific sub-
strates of T-cell protein tyrosine phosphatase. Mol. Cell. Biol. 18, 1622–1634.
Todd, J.A., Walker, N.M., Cooper, J.D., Smyth, D.J., Downes, K., Plagnol, V.,
Bailey, R., Nejentsev, S., Field, S.F., Payne, F., et al. (2007). Robust associa-
tions of four new chromosome regions from genome-wide analyses of type
1 diabetes. Nat. Genet. 39, 857–864.
Valentino, L., and Pierre, J. (2006). JAK/STAT signal transduction: regulators
and implication in hematological malignancies. Biochem. Pharmacol. 71,
713–721.van Vliet, C., Bukczynska, P.E., Puryer,M.A., Sadek, C.M., Shields, B.J., Trem-
blay, M.L., and Tiganis, T. (2005). Selective regulation of tumor necrosis factor-
induced Erk signaling by Src family kinases and the T cell protein tyrosine
phosphatase. Nat. Immunol. 6, 253–260.
Ward, I.M., and Chen, J. (2001). Histone H2AX is phosphorylated in an ATR-
dependent manner in response to replicational stress. J. Biol. Chem. 276,
47759–47762.
Weinert, T.A., Kiser, G.L., and Hartwell, L.H. (1994). Mitotic checkpoint genes
in budding yeast and the dependence of mitosis on DNA replication and repair.
Genes Dev. 8, 652–665.
WTCCC (Wellcome Trust Case Control Consortium) (2007). Genome-wide as-
sociation study of 14,000 cases of seven common diseases and 3,000 shared
controls. Nature 447, 661–678.
Xie, A., Puget, N., Shim, I., Odate, S., Jarzyna, I., Bassing, C.H., Alt, F.W., and
Scully, R. (2004). Control of sister chromatid recombination by histone H2AX.
Mol. Cell 16, 1017–1025.
Yamamoto, T., Sekine, Y., Kashima, K., Kubota, A., Sato, N., Aoki, N., andMat-
suda, T. (2002). The nuclear isoform of protein-tyrosine phosphatase TC-PTP
regulates interleukin-6-mediated signaling pathway through STAT3 dephos-
phorylation. Biochem. Biophys. Res. Commun. 297, 811–817.
Yeatman, T.J. (2004). A renaissance for SRC. Nat. Rev. Cancer 4, 470–480.
Yoo, H.Y., Kumagai, A., Shevchenko, A., and Dunphy,W.G. (2004). Adaptation
of a DNA replication checkpoint response depends upon inactivation of
Claspin by the Polo-like kinase. Cell 117, 575–588.Cancer Cell 14, 166–179, August 12, 2008 ª2008 Elsevier Inc. 179
